TCIM
ALT icon

TIAA CREF Investment Management’s Altimmune ALT Stock Holding History

TIAA CREF Investment Management’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,689
Closed -$411K – 3135
2017
Q1 		$411K Buy
1,689
+1,011
+149% +$541K ﹤0.01% 2853
2016
Q4 		$661K Buy
678
+7
+1% +$6.27K ﹤0.01% 2729
2016
Q3 		$584 Hold
671
– – ﹤0.01% 2788
2016
Q2 		$491K Buy
+671
New +$459K ﹤0.01% 2866

Other funds holding ALT

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FQ
First Quadrant Glendale, California $18M AUM 24.2% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

TIAA CREF Investment Management's ALT Position: Q2 2017 in Review

TIAA CREF Investment Management sold out of Altimmune (ALT) in Q2 2017, closing a stake of 1,689 shares — an estimated $411K sold.

TIAA CREF Investment Management first reported a position in ALT in Q2 2016 and held it in 4 quarters. The position peaked at $661K in Q4 2016. 41 funds tracked by Wall St. Rank hold ALT as of Q2 2017.

  • TIAA CREF Investment Management reported no remaining Altimmune position as of Q2 2017 after selling out during the quarter.
  • TIAA CREF Investment Management sold 1,689 Altimmune shares in Q2 2017, an estimated $411K.
  • TIAA CREF Investment Management first reported a position in Altimmune in Q2 2016 and held it in 4 quarters.
  • TIAA CREF Investment Management's Altimmune position peaked at $661K in Q4 2016.
  • 41 funds tracked by Wall St. Rank held Altimmune as of Q2 2017.

Based on TIAA CREF Investment Management's 13F filing for Q2 2017, filed 10 Aug 2017.